ClinicalTrials.gg
CompletedNCT06613763Updated Mar 5, 2025

A Study of RAY1225 in Participants With Impaired Kidney Function

A Phase 1 interventional study of RAY1225 in Kidney Impairment, sponsored by Guangdong Raynovent Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by Guangdong Raynovent Biotech Co., Ltd (part of Guangdong Zhongsheng Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies in Renal Insufficiency with a site in China — 16 open to participants now, 16 under way, none of them phase 3. Renal Insufficiency · China.

Enrollment
29th of 48
32 · median 41
Started
2024
with 6 others
Phase 1
22 of 61
4 open now
Registered
41st of 61
by date
Lead sponsor
3 of 61
Guangdong Raynovent Biotech Co., Ltd

Among the 61 studies in Renal Insufficiency with a site in China, this one is the 29th largest by enrollment of the 48 interventional ones that give a count, is one of 7 that started in 2024, is one of 22 in phase 1, and was the 41st registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

16 of the 61 studies in Renal Insufficiency with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Renal Insufficiency with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess how fast RAY1225 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.

03

Conditions studied

  • Kidney Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) ≥18 to ≤28kg/m2 and total body weight >50 kg(male) or >40kg(female) at Screening (calculated as a function of measured height and weight according to the formula, BMI = kg / m2 where m2 is height in meters squared);
  2. Ability to understand and willingness to sign a written form;

    Participants with normal renal function only:

  3. Normal physical examination, vital signs, 12-lead , Chest X-ray images (anteroposterior) and clinical laboratory values, or any abnormality that is non-;
  4. (GFR)≥ 90 mL/min and \<130 mL/min ;
  5. Age, BMI, and sex comparable to those of subjects of renal impairment;

    Participants with severe renal impairment only:

  6. Diagnosis of CKD (any indicators of renal impairment or GFR \< 60 mL/min/1.73 m2 for more than 3 months);

Exclusion criteria

Exclusion Criteria:

  1. Participants with an allergic disposition (multiple drug and food allergies) or who, have known allergies to RAY1225 or related compounds;
  2. Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2;
  3. Participants who donated blood or bleeding profusely (> 400 mL) in the 3 months or donated blood or bleeding profusely (> 200 mL) in the 1 months;
  4. Pregnant or lactating women, or women of childbearing age with a positive pregnancy test
  5. Participants with serious infections, trauma, gastrointestinal surgery or other major surgical procedures within 4 weeks

    Participants with severe renal impairment only:

  6. Participants with acute renal failure, or a kidney transplant history; or requiring renal dialysis during the study period;
  7. Hypertension that is not well controlled with antihypertensive medication (systolic blood pressure ≥ 160mm Hg or diastolic blood pressure ≥ 100mm Hg)
  8. (NYHA) class III or IV congestive heart failure
  9. (ALT) ≥ 2×, aspartate aminotransferase(AST) ≥ 2×ULN; Serum total > 1.5×ULN;
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    RAY1225 - Mild Renal Impairment

    RAY1225 3mg administered SC to participants with mild renal impairment.

    Drug: RAY1225

  • Experimental
    RAY1225 - Moderate Renal Impairment

    RAY1225 3mg administered SC to participants with moderate renal impairment.

    Drug: RAY1225

  • Experimental
    RAY1225 - Severe Renal Impairment

    RAY1225 3mg administered SC to participants with severe renal impairment.

    Drug: RAY1225

  • Experimental
    RAY1225 - Control

    RAY1225 3 milligrams (mg) administered subcutaneously (SC) to healthy participants with normal renal function.

    Drug: RAY1225

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of RAY1225 From Time Zero to T (AUC[0-t])

    Time frame: Baseline through Day 43

  2. PK: Maximum Concentration of RAY1225

    Time frame: Baseline through Day 43

Secondary outcomes

  1. Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE)

    Time frame: Baseline through Day 43

07

Study locations

1 site
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2024 to primary completion in Jan 2025, 3 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Sep 26, 2024
StartActual
Sep 11, 2024
Primary completionActual
Jan 10, 2025
CompletionActual
Jan 20, 2025
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06613763
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
Sep 11, 2024
Primary completion
Jan 10, 2025
Completion
Jan 20, 2025
Last update
Mar 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bilpatide

Start the discussion